[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 247
1. Bachmann A: Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):435-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment on: transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • (PMID = 18069122.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  •  go-up   go-down


2. Davis A, Goel S, Picolos M, Wang M, Lavis V: Pituitary apoplexy after leuprolide. Pituitary; 2006;9(3):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically unsuspected pituitary adenomas are common among adults on autopsy and MRI survey.
  • We report a case of a 61-year-old male patient with locally advanced prostate cancer who presented with an acute picture of pituitary apoplexy after his first dose of leuprolide.
  • Initial stimulatory effects of gonadotropin releasing hormone (GnRH) analogue may induce apoplexy in patients with asymptomatic gonadotroph adenomas.
  • [MeSH-major] Adenoma / complications. Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Leuprolide / adverse effects. Pituitary Apoplexy / chemically induced. Pituitary Neoplasms / complications. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1990 Dec;144(6):1479-80 [2122011.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):675-9 [8010269.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Jan;44(1):121-4 [8706284.001]
  • [Cites] J Endocrinol Invest. 1997 Oct;20(9):566-8 [9413812.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2267-8 [7608291.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):542-5 [11561045.001]
  • [Cites] Intern Med J. 2001 Jul;31(5):313-4 [11512605.001]
  • [Cites] Radiology. 1994 Oct;193(1):161-4 [8090885.001]
  • [Cites] Neurosurgery. 1984 Mar;14(3):363-73 [6369168.001]
  • [Cites] Lancet. 1995 Feb 18;345(8947):458 [7853980.001]
  • [Cites] N Engl J Med. 1991 Jan 10;324(2):93-103 [1984190.001]
  • [Cites] Acta Endocrinol (Copenh). 1984 Oct;107(2):149-54 [6437103.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Aug;51(2):181-8 [10468988.001]
  • (PMID = 16832587.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


3. Zmerli S: [My life in urology]. Tunis Med; 2008 Nov;86(11):949-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Mon vécu de l'urologie.
  • If urinary lithiasis, prostate adenoma, bladder tumor and urethra stricture constituted the majority of my activity, many other diseases specific to the Maghreb should be mentioned such as fistula between bladder and vaginal arising after obstetrical maneuvers and hydatid cyst of the kidney.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19213482.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Autobiography; Biography; English Abstract; Historical Article; Journal Article
  • [Publication-country] Tunisia
  • [Personal-name-as-subject] Zmerli S
  •  go-up   go-down


Advertisement
4. Csomor J, Kaszás I, Kollár B, Pajor L, Egyházi Z, Fekete S, Egyed M, Timár B: Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma. Pathol Oncol Res; 2008 Sep;14(3):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma.
  • Here we report a case of a 73-year-old man with primary intravascular large B-cell lymphoma localized to the prostate.
  • Total prostatectomy was performed due to a benign adenoma suggested by ultrasonography.
  • The diagnosis of IVLBL was obtained incidentally from the prostatectomy specimen.
  • Primary prostate IVLBL is extremely uncommon; to date only four cases have been described.
  • Successful treatment depends on early diagnosis of IVLBL, aggressive chemotherapy and the fact that IVLBL should be considered as a generalized disease in spite of negative staging results.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2004 May 01;89(5):ECR13 [15136242.001]
  • [Cites] Br J Haematol. 2007 Mar;136(5):684 [17129231.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Br J Haematol. 2002 Oct;119(1):2 [12358897.001]
  • [Cites] Oncologist. 2006 Sep;11(8):923-8 [16951396.001]
  • [Cites] Hum Pathol. 2000 Feb;31(2):220-6 [10685637.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):564-5 [12560450.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Mar;34(3):189-90 [15938838.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):74-8 [16867907.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):693-9 [15832096.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):732-8 [9708938.001]
  • [Cites] Rev Med Chil. 2004 Nov;132(11):1403-6 [15693204.001]
  • (PMID = 18493873.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide; IEV protocol
  •  go-up   go-down


5. Weissbach L, Ebert T, Schmitz-Dräger B: [Taking stock after 400 days: the effects on ambulatory care from a medical point of view]. Z Arztl Fortbild Qualitatssich; 2006;100(1):40-3; discussion 44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taking the contract signed with the AOK Bavaria and comprising the integrated care of patients with prostate carcinoma, prostate adenoma and prostatitis as an example the contents and consequences of this agreement will be described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524229.001).
  • [ISSN] 1431-7621
  • [Journal-full-title] Zeitschrift für ärztliche Fortbildung und Qualitätssicherung
  • [ISO-abbreviation] Z Arztl Fortbild Qualitatssich
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • Nephrogenic adenoma is a benign lesion that may occur at any site of the genitourinary tract, usually in association with previous urothelial injuries.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • Alpha-methylacyl-CoA racemase (AMACR), a recently identified prostate cancer marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • (3) given that both S100A1 and AMACR have been reported to be expressed in renal tubular cells and in a subset of renal cell neoplasms, our findings confirm the histogenetic relationship between nephrogenic adenoma and renal tubular epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


7. Rózański W, Klimek L, Jabłonowski Z, Sosnowski M: Assessment of neodymium:yttrium-aluminum-garnet (Nd:YAG) laser fiber wear and tear grade during visual laser ablation of prostatic adenoma. Photomed Laser Surg; 2009 Oct;27(5):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of neodymium:yttrium-aluminum-garnet (Nd:YAG) laser fiber wear and tear grade during visual laser ablation of prostatic adenoma.
  • MATERIALS AND METHODS: Nd:YAG laser and Urolase noncontact fibers with 7.5 F gold reflective surface tips have been used to treat benign prostatic hyperplasia since 1995.
  • [MeSH-major] Equipment Failure Analysis. Laser Therapy / instrumentation. Lasers, Solid-State. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19878030.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kapur U, Katz RL: Radioactive iodine-associated changes in thyroid on fine-needle aspiration. Diagn Cytopathol; 2010 Feb;38(2):119-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / complications. Biopsy, Fine-Needle. Humans. Hyperparathyroidism / complications. Male. Middle Aged. Parathyroid Neoplasms / complications. Prostatic Neoplasms / surgery. Venous Thrombosis / complications

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19459169.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


9. Mazo EB, Sergeeva NA, Grigor'ev ME, Lebedev DV, Solov'eva EV, Konorev VA, Krovets AA: [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer]. Urologiia; 2006 May-Jun;(3):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer].
  • The aim of the study was to compare diagnostic significance of free PSA (fPSA)/total PSA (tPSA) versus PSA complex with alpha1-antichymotrypsin (cPSA) in tPSA level within 4-10 ng/ml in differential diagnosis of prostatic cancer (PC).
  • A complete urological examination (digital rectal test, transrectal ultrasound investigation, serum assay for fPSA and tPSA, multifocal transperineal prostatic biopsy) was made in 108 patients with tPSA blood level 4-10 ng/ ml.
  • Prostatic adenoma (PA) was histologically verified in 61 of 108 patients, fPSA/tPSA was normal.
  • A course of etiotropic therapy of chronic prostatic inflammation produced no significant changes in fPSA/tPSA and cPSA in 28 out of 39 patients.
  • Thus, cPSA in PC suspects is more informative than fPSA/tPSA in PC diagnosis.
  • CPSA in the serum depends on prostatic inflammation making difficult differential diagnosis of PC in interpretation of tPSA, fPSA/tPSA and cPSA.
  • Therefore, estimation of PSA variants and molecular forms in PC suspects and prostatic inflammation should be made after etiotropic therapy.
  • [MeSH-major] Antigens, Surface / blood. Biomarkers, Tumor / blood. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. alpha 1-Antichymotrypsin / blood


10. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol; 2006 Jan;13(1):87-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
  • We report the case of a T3 prostate cancer in a 70-year-old white man.
  • Hormone therapy represents a prominent branch in the treatment of locally advanced and metastatic prostate cancer.
  • This phenomenon may be noxious in the case of gonadotroph adenoma, with subsequent symptoms of intracranial hypertension.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Leuprolide / adverse effects. Pituitary Neoplasms / chemically induced. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448441.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


11. Guerra Y, Lacuesta E, Marquez F, Raksin PB, Utset M, Fogelfeld L: Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer. Pituitary; 2010;13(1):54-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer.
  • We report the case of a 60 year old male who complained of headache and blurry vision--that progressed to left ophthalmoplegia and ptosis--after receiving a dose of leuprolide for Prostate cancer therapy.
  • A literature review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer.
  • [MeSH-major] Adenoma / complications. Leuprolide / adverse effects. Pituitary Neoplasms / complications. Stroke / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Humans. Male. Middle Aged. Prostatic Neoplasms / complications. Prostatic Neoplasms / drug therapy. Sella Turcica


12. Bensalah K, Fleureau J, Rolland D, Rioux-Leclercq N, Senhadji L, Lavastre O, Guillé F, Patard JJ, de Crevoisier R: [Optical spectroscopy: a new approach to assess urological tumors]. Prog Urol; 2010 Jul;20(7):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La spectroscopie optique : une nouvelle approche pour l'étude des tumeurs urologiques.
  • Several publications specifically aimed at assessing prostate cancers, renal carcinomas and urothelial tumors.
  • Optical spectroscopy can differentiate benign (adenoma or inflammation) and malignant (adenocarcinoma) prostatic tissues.
  • Regarding renal tumors, spectroscopy can identify normal and tumoral tissue and differentiate benign and malignant tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20656268.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  •  go-up   go-down


13. Gomberg VG, Nad' IuT: [Efficacy of Vitaprost Forte in the treatment of adenoma]. Urologiia; 2010 Sep-Oct;(5):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of Vitaprost Forte in the treatment of adenoma].
  • Pharmacotherapy with vitaprost forte was given to 40 patients with prostatic adenoma aged 55 to 77 years (mean age 67.6 +/- 0.9 years).
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254638.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Suppositories; 0 / Vitaprost
  •  go-up   go-down


14. Endo F, Shiga Y, Minagawa S, Iwabuchi T, Fujisaki A, Yashi M, Hattori K, Muraishi O: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence. Urology; 2010 Dec;76(6):1451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-eight consecutive patients with benign prostatic hyperplasia underwent HoLEP from January to December 2008.
  • The next 37 cases (Surgery 2) underwent anteroposterior dissection HoLEP, where adenoma was dissected antegradely.
  • Surgical quality indexes (hemoglobin change, operating time, resected prostate volume) between the 2 groups were compared.
  • All patients were assessed at 2 weeks postoperatively for clinical SUI, international prostate symptom score (IPSS), quality of life (QoL), and peak flow rates (Q(max)).
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Urinary Incontinence, Stress / prevention & control
  • [MeSH-minor] Aged. Dissection / methods. Humans. Learning Curve. Male. Middle Aged. Mucous Membrane / surgery. Organ Size. Prostate / pathology. Quality of Life. Retrospective Studies


15. Pavlov VN, Kazikhinurov AA, Ishemgulov RR, Mustafin AT: [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method]. Urologiia; 2008 Jan-Feb;(1):31-2, 34-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method].
  • To determine microcirculation in the wall of the urinary bladder in prostatic adenoma, we used a laser analyzer of capillary circulation LAKK-01.
  • Two groups participated in the trial: 105 males with stage II prostatic adenoma (the study group) and 25 volunteers (the control group).
  • In stage II prostatic adenoma the above microcirculation decreased to a subcritical perfusion level.
  • Significantly earlier and complete recovery of microcirculation was observed in patients who had taken cardura (Pfizer) in a dose 2 mg/day for 3 months after transurethral resection of prostatic gland.
  • Thus, 2 mg/day cardura (Pfizer) in patients with prostatic adenoma of stage II after TUR of the prostate promotes early and effective recovery of microcirculation.
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Recovery of Function. Urinary Bladder / blood supply

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649676.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; NW1291F1W8 / Doxazosin
  •  go-up   go-down


16. Matlaga BR, Miller NL, Lingeman JE: Holmium laser treatment of benign prostatic hyperplasia: an update. Curr Opin Urol; 2007 Jan;17(1):27-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Holmium laser treatment of benign prostatic hyperplasia: an update.
  • PURPOSE OF REVIEW: The surgical treatment of benign prostatic hyperplasia is a dynamic, evolving field.
  • Holmium laser enucleation of the prostate has been one of the most rigorously analyzed interventions for benign prostatic hyperplasia.
  • RECENT FINDINGS: In the 12-month period of this review, there have been a number of articles published on holmium laser enucleation of the prostate.
  • These studies emphasize the unique advantages of holmium laser enucleation of the prostate over other surgical treatments for benign prostatic hyperplasia.
  • SUMMARY: Holmium laser enucleation of the prostate is a more efficient procedure than competitor techniques, when grams of tissue removed per unit time are quantified.
  • Additionally, holmium laser enucleation of the prostate is associated with a reduced length of catheterization and hospitalization when compared with other surgical therapies for men with benign prostatic hyperplasia.
  • Outcome measures for men undergoing holmium laser enucleation of the prostate are in many cases superior to those of other modalities.
  • It is likely that the completeness of adenoma removal with holmium laser enucleation of the prostate confers many of these advantages.
  • [MeSH-major] Holmium. Laser Therapy / trends. Prostate / surgery. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / trends

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143108.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  • [Number-of-references] 18
  •  go-up   go-down


17. Pushkar' DIu, Rasner PI: [Modern algorithm of examination and treatment of patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):87-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern algorithm of examination and treatment of patients with prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Adrenergic alpha-Antagonists / pharmacokinetics. Adrenergic alpha-Antagonists / therapeutic use. Algorithms. Cholestenone 5 alpha-Reductase / antagonists & inhibitors. Diagnosis, Differential. Enzyme Inhibitors / administration & dosage. Enzyme Inhibitors / pharmacokinetics. Enzyme Inhibitors / therapeutic use. Humans. Male. Urination / physiology. Urination Disorders / diagnosis. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722625.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; EC 1.3.1.22 / Cholestenone 5 alpha-Reductase
  •  go-up   go-down


18. Sinnadurai M, Cherukuri RK, Moses RG, Nasser E: Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists. J Clin Neurosci; 2010 Sep;17(9):1201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
  • Gonadotrophin-releasing hormone agonists (GnRHAs) are used in many clinical conditions, particularly prostate cancer.
  • Two months before presentation, he had a subcutaneous GnRHA (Goserelin) implant for treatment of locally advanced prostate cancer (Gleeson 4+3).
  • His vision improved post-operatively and his FSH, LH, testosterone, prostate specific antigen (PSA) levels returned to normal levels.
  • Histopathologic studies revealed a pituitary adenoma, which stained positive for FSH and LH.
  • The prostate cancer management was changed to an anti-androgen agent and a GnRH antagonist.
  • This case demonstrates that pituitary apoplexy can develop up to eight weeks after the initiation of treatment for prostate cancer with GnRHAs.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Goserelin / adverse effects. Pituitary Apoplexy / chemically induced. Pituitary Apoplexy / diagnosis. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2010. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20605467.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Drug Implants; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


19. Modi P, Helfand BT, McVary KT: Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Curr Urol Rep; 2010 Jul;11(4):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.
  • Prostate-specific antigen (PSA) is the most widely used marker for prostate cancer (CaP) screening and monitoring benign prostatic hyperplasia (BPH) progression.
  • However, lack of an established abnormal threshold and the presence of other benign processes confound the interpretation of PSA levels.
  • For example, the commonly used 5 alpha reductase inhibitor (5ARI) medications directly affect PSA levels by decreasing prostate volume.
  • The amount of time and potentially even the 5ARI formulary a patient is administered has been implicated to directly impact the degree of reduction in PSA (a proxy for prostate volume).
  • In addition, each of the currently available surgical procedures for BPH appears to remove varying amounts of prostatic adenoma.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / therapy


20. Lepage JY, Rivault O, Karam G, Malinovsky JM, Le Gouedec G, Cozian A, Malinge M, Pinaud M: [Anaesthesia and prostate surgery]. Ann Fr Anesth Reanim; 2005 Apr;24(4):397-411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaesthesia and prostate surgery].
  • [Transliterated title] Anesthésie et chirurgie de la prostate.
  • OBJECTIVES: To review the current data about anaesthetic management in prostate surgery with special regards on analysis and prevention of specific risks, appropriate anaesthetic procedure keeping with surgery and patient, recognition and treatment of adverse events.
  • Preoperative evaluation of cardiovascular, respiratory, neurological and metabolic comorbidity is a source of prognostic information and an essential tool in the management of elderly patients with prostate disease.
  • Extreme patient positioning applied in prostate surgery induces haemodynamic and respiratory changes and are associated with severe muscular and nervous injuries.
  • Whether open transvesical or transurethral prostatectomy for treatment of benign hypertrophy depends on the size of the gland: transurethral resection is safe up to 80 g.
  • Intrathecal anaesthesia with a T9 cephalad spread of sensory block, produces adequate conditions for transurethral prostatectomy and allows a rapid diagnosis of irrigating fluid absorption syndrome.
  • In spite of recommended preoperative antibiotic prophylaxis, bacteriemias are frequent during transurethral prostate resection.
  • [MeSH-major] Anesthesia. Prostate / surgery. Urogenital Surgical Procedures
  • [MeSH-minor] Adenoma / surgery. Humans. Intraoperative Complications / epidemiology. Intraoperative Complications / prevention & control. Male. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Preoperative Care. Prostatectomy / adverse effects. Prostatic Neoplasms / surgery. Risk Factors

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15826790.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 186
  •  go-up   go-down


21. Oktay B, Vuruskan H, Koc G, Danisoglu ME, Kordan Y: Single-port extraperitoneal transvesical adenomectomy: initial operative experience. Urol Int; 2010;85(2):131-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Laparoscopic extraperitoneal adenomectomy is occasionally performed for symptomatic large-volume benign prostatic hyperplasia.
  • A transverse cystotomy adjacent to the prostatovesical junction, incision of mucosa overlying the adenoma, subcapsular plane development, prostatic adenomectomy and cystotomy repair were performed as the standard steps of the laparoscopic procedure.
  • CONCLUSIONS: Single-port extraperitoneal transvesical adenomectomy for large benign prostate hyperplasia is feasible with excellent cosmetic results and minimal morbidity.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20558978.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


22. Markov AV, Luk'ianov IV, Loran OB: [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy]. Urologiia; 2007 Jul-Aug;(4):41-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy].
  • Rehabilitation therapy was performed in 5 groups (n=122) of patients operated for prostatic adenoma (TUR of the prostate, transvesical prostatectomy) and having postoperative marked irritative miction disorders.
  • Thus, adjuvant physiotherapy inclusion in the complex of postoperative rehabilitation of patients operated for prostatic adenoma is justified as it improves treatment efficacy.
  • [MeSH-major] Prostatic Hyperplasia / rehabilitation. Urinary Incontinence / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Follow-Up Studies. Humans. Male. Middle Aged. Prostate / surgery. Prostatectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915448.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


23. Coleman JF, Hansel DE: Benign Diseases of the Bladder. Surg Pathol Clin; 2008 Dec;1(1):129-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Diseases of the Bladder.
  • Benign diseases of the bladder often present diagnostic challenges to practicing pathologists due to their diverse nature and ability to mimic a variety of epithelial or mesenchymal neoplasms.
  • Categories of benign bladder disease include infectious cystitis, noninfectious cystitis, reactive proliferative processes, and benign processes that secondarily involve the bladder.
  • An understanding of the key clinical and morphologic features of these lesions and the useful ancillary techniques specific for these entities is critical to the correct diagnosis of these lesions.
  • This article reviews the key features of these benign bladder diseases and highlights methods to distinguish these lesions from other benign and malignant processes involving the bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Inc. All rights reserved.
  • (PMID = 26837905.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Amyloidosis / Benign bladder diseases / Bladder / Bladder pathology / Cystitis cystica / Cystitis glandularis / Ectopic prostatic tissue / Endometriosis / Eosinophilic cystitis / Fungal cystitis / Granulomatous cystitis / Histology / Infection / Inflammation / Interstitial cystitis / Malakoplakia / Mimickers / Nephrogenic adenoma / Pathology / Polyomavirus infection / Polypoid cystitis / Reactive response / Therapy-induced cystitis / Von Brunn's nests
  •  go-up   go-down


24. Senarriaga Ruiz de la Illa N, Loizaga Iriarte A, Iriarte Soldevilla I, Lacasa Viscasillas I, Unda Urzaiz M: Pelvic hydatid disease as an example of pelvic masses of uncertain aetiology. Actas Urol Esp; 2009 Nov;33(10):1129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The other case of pelvic hydatid disease was asymptomatic, and was discovered by chance while examining a 75 year-old man for a prostatic adenoma.
  • The pathology confirmed the diagnosis in the first case and radiological findings confirmed the second.
  • Hydatid disease must be considered in the differential diagnosis of any cystic masses in the pelvic organs, especially in countries where the disease is endemic.
  • [MeSH-major] Echinococcosis / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096185.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


25. Coletti Moja M, Milano E, Gasverde S, Gianelli M, Giordana MT: Olanzapine therapy in hallucinatory visions related to Bonnet syndrome. Neurol Sci; 2005 Jul;26(3):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No cognitive impairment and no diseases apart from prostatic adenoma treated with alpha-lythic therapy were reported.

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • Hazardous Substances Data Bank. Olanzapine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086130.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 12794-10-4 / Benzodiazepines; 132539-06-1 / olanzapine
  •  go-up   go-down


26. Hansel DE, Nadasdy T, Epstein JI: Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma. Am J Surg Pathol; 2007 Aug;31(8):1231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromyxoid nephrogenic adenoma: a newly recognized variant mimicking mucinous adenocarcinoma.
  • Nephrogenic adenomas demonstrate a variety of morphologic patterns that may occasionally be confused with malignant processes, including urothelial and prostatic carcinoma.
  • In this series, we describe 8 cases of nephrogenic adenoma that contain an admixture of the classic tubular form of nephrogenic adenoma and an unusual spindled and fibromyxoid form of nephrogenic adenoma that closely mimics infiltrating carcinoma.
  • In all cases, the classic tubular form of nephrogenic adenoma composed only a small proportion of the lesion, whereas the remainder consisted of compressed spindled cells within a fibromyxoid background, with only rare tubular and cordlike structures.
  • All 8 patients were elderly men who had a prior or concurrent history of acinar prostate cancer (n=4), combined acinar prostate and urothelial carcinoma (n=1), urothelial-type adenocarcinoma of the prostate (n=1), bladder urothelial carcinoma (n=1), or no prior reported prostatic or urothelial abnormalities (n=1).
  • Immunostains for prostate-specific antigen were negative.
  • This case series is the first report of a fibromyxoid subtype of nephrogenic adenoma.
  • Awareness of this entity and the use of ancillary techniques can aid in the diagnosis of this unusual form of nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenoma / pathology. Fibroma / pathology. Urologic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Middle Aged. Mucins / analysis. Neoplasms, Multiple Primary. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667548.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins
  •  go-up   go-down


27. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. Urologiia; 2006 Nov-Dec;(6):83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].
  • [MeSH-major] Azasteroids / therapeutic use. Cholestenone 5 alpha-Reductase / antagonists & inhibitors. Enzyme Inhibitors / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315721.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Azasteroids; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; EC 1.3.1.22 / Cholestenone 5 alpha-Reductase; O0J6XJN02I / Dutasteride
  • [Number-of-references] 34
  •  go-up   go-down


28. Martella O, Galatioto GP, Pace G, Vicentini C: PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia. Arch Ital Urol Androl; 2010 Dec;82(4):139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia.
  • It is known that serum prostate-specific antigen levels (PSA) decrease gradually following surgery for benign prostatic hyperplasia (BPH), but there is not an established cut-off value for normal PSA after relief of obstruction.
  • We evaluated the impact of prostatic adenoma enucleation on PSA levels in 110 patients who underwent transvesical suprapubic adenomectomy for symptomatic BPH.
  • We examined PSA levels before and after open surgery and weight of the prostatic adenoma as measured by the pathologist.
  • In patients with suspected abnormality on digital rectal examination or PSA > 4.0 ng/mL systematic multisite biopsies were performed preoperatively to rule out prostate cancer.
  • The mean weight of enucleated adenoma was 87 gr (range 50-201).
  • PSA supernormalisation represents an objective measure of complete adenoma removal.


29. Trapeznikova MF, Dutov VV, Dolgovq AG, Urenkov SB: [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis]. Urologiia; 2008 Sep-Oct;(5):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis].
  • We studied efficacy and safety of prostamol-Uno (PU) monotherapy in patients with prostatic adenoma (PA) comorbid with chronic abacterial prostatitis (CAP) in a clinical open trial including 45-year-old males aged over 45 years with PA comorbid with CAP, having irritative and obstructive symptoms by IPSS above 8 points and duration 6 months or longer, by NIH-CPSI above 10 points and duration 3 months or longer.
  • The patients had Qmax from 5 to 15 ml/s, urine volume 100-350 ml, residual urine volume under 150 ml, prostate size more than 25 cm3, PSA level under 4 ng/ml and no bacterial growth in the third urine portion seeding and/or prostatic secretion.
  • The effect was assessed by the disease history, complaints, digital rectal examination of the prostate, the disease symptoms by IPSS, quality of life (QoL), NIH-CPSI, bacteriological tests of the urine and prostatic secretion, urinalysis, Nechiporenko test in 3 urine portions.
  • Uroflowmetry, ultrasonic investigation of the urinary bladder and prostate, transrectal energy dopplerography of the prostate, PSA assay in the blood serum were made in all the patients.
  • Spectral doppler examination detected improvement in prostatic blood flow after PU treatment in 16 (53.3%) patients.
  • Thus, PU effectively reduces irritative and obstructive symptoms typical for prostatic adenoma in combination with CAP.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Blood Pressure / drug effects. Chronic Disease. Electrocardiography. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Quality of Life. Urination / drug effects


30. Sato K, Tachibana H, Tsuzuki T, Ueda Y, Katsuda S: Prostatic ductal adenocarcinoma mimicking villous adenoma of the urethra. Virchows Arch; 2006 Nov;449(5):597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic ductal adenocarcinoma mimicking villous adenoma of the urethra.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Ductal / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Cancer. 1973 Aug;32(2):402-9 [4124700.001]
  • [Cites] Cancer. 1967 Oct;20(10):1715-22 [4168340.001]
  • [Cites] Urology. 1994 May;43(5):737-42 [7513110.001]
  • (PMID = 16988838.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


31. Hautmann RE, Stein JP: Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am; 2005 May;32(2):177-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction.
  • The modified procedure includes cystectomy with sparing of prostate, vasa deferens, seminal vesicles, and resection of a prostatic adenoma to avoid bladder outlet obstruction and bladder reconstruction with an orthotopic reservoir.
  • Furthermore, surgeons considering procedures that preserve a portion of the prostatic urethra, the prostatic capsule, or the entire prostate should recognize a 6% risk of significant prostatic cancer in any residual tissue, and the potential risk of urethral tumor involvement with TCC.
  • [MeSH-minor] Humans. Male. Patient Selection. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Seminal Vesicles. Treatment Outcome


32. Lang F, Perrotti N, Stournaras C: Colorectal carcinoma cells--regulation of survival and growth by SGK1. Int J Biochem Cell Biol; 2010 Oct;42(10):1571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Following deficiency of APC (adenoma polyposis coli) or chemical cancerogenesis, SGK1 knockout mice develop less intestinal tumours than their wild-type littermates and pharmacological SGK1 inhibition counteracts growth of prostate cancer cells.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Immediate-Early Proteins / metabolism. Prostatic Neoplasms / metabolism. Protein-Serine-Threonine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20541034.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Immediate-Early Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / serum-glucocorticoid regulated kinase
  •  go-up   go-down


33. Mazo EB, Krivoborodov GG, Shkol'nikov ME, Efremov NS: [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer]. Urologiia; 2008 Jul-Aug;(4):63-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Botulinic toxin of type A in the treatment of prostatic adenoma and cancer].
  • [MeSH-major] Botulinum Toxins, Type A / therapeutic use. Neuromuscular Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Botox.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058365.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 37
  •  go-up   go-down


34. Bratchikov OI, Ambarian AA, Shumakova EA, Khmaruk AP, Kriukov AA, Trifonov EIu, Mikhaĭlov DV, Abduldzhalil Shukri MA: [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma]. Urologiia; 2010 Jan-Feb;(1):38-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma].
  • The aim of our study was to assess the causes of renal failure in patients with prostatic adenoma (PA) and outcomes after draining of the urinary bladder.
  • We found that age, prostate volume, PA growth pattern, urinary tract infection, concomitant pathology (arterial hypertension, diabetes mellitus, atherosclerosis) do not correlate with a serum creatinine level.
  • [MeSH-major] Creatinine / blood. Prostatic Hyperplasia / complications. Renal Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886730.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


35. Kamalov AA, Efremov EA, Dorofeev SD, Paniushkin SM: [Use of oral vitaprost in the treatment of chronic abacterial prostatitis]. Urologiia; 2006 Sep-Oct;(5):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An open trial performed in 2001 by the Research Institute of Urology has demonstrated good efficacy and safety of rectal suppositoria Vitaprost, the active substance of which is a complex of water-soluble biologically active peptides isolated from bovine prostate, in combined treatment of chronic bacterial and abacterial prostatitis in patients of all ages including those with concomitant adenoma.
  • Current comparative clinical trial has shown that Vitaprost tablets in combination with nonsteroid anti-inflammatory drugs effectively treat prostatic inflammation in patients with chronic abacterial prostatitis, produce more potent and stable effect than monotherapy with ketonal.

  • Genetic Alliance. consumer health - Prostatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444152.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Peptides; 90Y4QC304K / Ketoprofen
  •  go-up   go-down


36. Iwamoto K, Hiraoka Y, Shimizu Y: Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia. J Nippon Med Sch; 2008 Apr;75(2):77-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral detachment prostatectomy using a tissue morcellator for large benign prostatic hyperplasia.
  • OBJECTIVE: Transurethral enucleation of the prostate (TUE) is designed for complete removal of the prostate lobes.
  • On the basis of TUE and holmium laser enucleation of the prostate, we developed a new technique of transurethral detachment prostatectomy (TUDP) using a tissue morcellator.
  • MATERIALS AND METHODS: In TUDP, enucleation is performed with a prostate-detaching blade and the tip of a resectoscope, followed by removal of the tissue with a morcellator.
  • This study reports our experience with TUDP in which the weight of retrieved tissue was greater than 30 g in 76 patients with benign prostate hyperplasia.
  • RESULTS: The mean preoperative total prostate and adenoma volumes were 70.7 and 47.4 mL, respectively.
  • The mean weight of removed prostate tissue was 61.1 g.
  • The mean preoperative maximum flow rate (Qmax), International Prostate Symptom Score (IPSS), and quality of life score (QOL) improved from 9.8 mL/sec, 20.2, and 4.9, to 22.3 mL/sec, 3.1 and 1.2, respectively.
  • The mean prostate volume and serum prostate-specific antigen level measured 6 months postoperatively in 46 patients were 10.68 mL and 0.89 ng/mL, respectively.
  • CONCLUSIONS: TUDP is effective for complete removal of large prostate lobes in patients with large benign prostate hyperplasia and is associated with lower perioperative morbidity.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Organ Size. Postoperative Complications. Prostate / pathology

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18475027.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Mariano MB, Tefilli MV, Graziottin TM, Morales CM, Goldraich IH: Laparoscopic prostatectomy for benign prostatic hyperplasia--a six-year experience. Eur Urol; 2006 Jan;49(1):127-31; discussion 131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic prostatectomy for benign prostatic hyperplasia--a six-year experience.
  • PURPOSE: The Authors present their results using laparoscopic prostatectomy in the treatment of large benign prostatic hyperplasia (BPH).
  • RESULTS: The average prostate weight was 144.50+/-41.74 gm.
  • CONCLUSIONS: The results demonstrate that resection of large prostatic adenomas can be performed with a laparoscopic approach.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery


38. Cohen RJ, Shannon BA: Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma. Pathology; 2007 Oct;39(5):522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of the prostatic urethra: a rare and usually indolent lesion distinct from prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / pathology. Diverticulum / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886106.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


39. Shakhmachev VN: [Comparative evaluation of hemostatic methods during open adenomectomy]. Urologiia; 2010 Nov-Dec;(6):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The article compares effectiveness of different methods of hemostasis after transvesical adenomectomy for prostatic adenoma practiced in the world and presents original experience in surgical treatment of 224 patients with prostatic adenoma.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Hemostasis, Surgical / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427988.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


40. Yoon CY, Sung DJ, Lee JH, Kim AR, Oh CW, Je JH, Weon BM, Seol SK, Pyun A, Hwu Y, Margaritondo G, Joo KJ, Yoon DK: Imaging of renal and prostate carcinoma with refractive index radiology. Int J Urol; 2007 Feb;14(2):96-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of renal and prostate carcinoma with refractive index radiology.
  • In this study the potential of refractive index radiology was evaluated for the imaging of renal cell carcinoma (RCC) and prostate cancer (PCA).
  • The radiographic images of the prostate were comparable with those of low magnification optical microscopy, providing good visualization of normal microstructures such as adenoma, smooth muscle, and normal glands, or differentiation of tiny tumors from surrounding normal tissues.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17302563.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


41. Blah M, Nouira Y, Kallel Y, Hafsia GH, Horchani A: [Bladder herniation]. Ann Chir; 2005 Dec;130(10):633-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis is frequently done during surgery.
  • Retrograde urethrocystography or computerized tomography confirm the diagnosis.
  • We report a case of bilateral inguinal hernia involving the bladder at the right side in a 87 years old man who had a surgical history of transvesical adenomectomy of the prostate.
  • The diagnosis was done on the retrograde urethrocystography.
  • [MeSH-minor] Adenoma / surgery. Aged. Functional Laterality. Humans. Male. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043116.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


42. Józsa LG: Histologic diagnoses of tissues from two nineteenth century Habsburgs. Paleopathol Newsl; 2008 Mar;(141):12-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gout (urate nephropathy), severe arteriosclerosis, prostate adenoma and purulent prostatitis could also be diagnosed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831390.001).
  • [ISSN] 0148-4737
  • [Journal-full-title] Paleopathology newsletter
  • [ISO-abbreviation] Paleopathol Newsl
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Habsburg J; Romanova AP
  •  go-up   go-down


43. Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT: Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology; 2009 Jul;74(1):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
  • OBJECTIVES: To determine whether prostate-specific antigen (PSA) values can distinguish those with prostate cancer (CaP) from those with histologic benign prostatic hyperplasia (BPH) only after surgical intervention.
  • Prostatic adenoma inevitably remains after BPH surgery; therefore, patients remain at risk of developing CaP.
  • METHODS: We performed a review of patients who had undergone transurethral resection of the prostate (TURP; n = 343), holmium laser resection of the prostate (HoLRP; n = 54), or open prostatectomy (OP; n = 68).
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


44. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • Clinical variables were compared between patients with and without carcinoma involving the prostate using standard statistical software.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • There were 9 patients (26%) who had urothelial carcinoma involving the prostate; only prostatic urethral biopsy identified these patients before radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Graziotti P, Giusti G, Seveso M, Taverna G, Benetti A, Maugeri O, Pasini L, Zandegiacomo S, Piccinelli A, Maffezzini M: Retropubic nerve and seminal sparing radical prostatectomy for recurrent bladder neck-prostatic urethra strictures. Arch Ital Urol Androl; 2005 Dec;77(4):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retropubic nerve and seminal sparing radical prostatectomy for recurrent bladder neck-prostatic urethra strictures.
  • OBJECTIVES: To verify if nerve and seminal sparing radical prostatectomy could represent surgical solution for iatrogenic bladder neck prostatic urethra contracture without external sphincter involvement.
  • MATERIAL AND METHODS: At our institution 4 patients have been submitted to nerve and seminal sparing radical prostatectomy for recurrent bladder neck-prostatic urethra contracture following TURP for middle size adenoma.
  • CONCLUSION: Even though our experience is very limited in terms of number of patients and length of follow-up, we think that nerve and seminal sparing radical prostatectomy, because of the limited risk of major complications and the good result in terms of preservation of both urinary continence and erectile function, can be a reasonable solution for iatrogenic bladder neck-prostatic contracture after prostatic surgery for BPH.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444927.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ: Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol; 2010 Jan 21;8:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells.
  • We recently demonstrated that sensitivity to low folate availability is affected by the rate of polyamine biosynthesis, which is prominent in prostate cells.
  • We, therefore, hypothesized that prostate cells might be highly susceptible to genetic, epigenetic and phenotypic changes consequent to folate restriction.
  • RESULTS: We studied the consequences of long-term, mild folate depletion in a model comprised of three syngenic cell lines derived from the transgenic adenoma of the mouse prostate (TRAMP) model, recapitulating different stages of prostate cancer; benign, transformed and metastatic.
  • High-performance liquid chromatography analysis demonstrated that mild folate depletion (100 nM) sufficed to induce imbalance in both the nucleotide and AdoMet pools in all prostate cell lines.
  • These genomic changes coincided with phenotype changes in the prostate cells including increased anchorage-independent growth and reduced sensitivity to folate depletion.
  • CONCLUSIONS: This study demonstrates that prostate cells are highly susceptible to genetic and epigenetic changes consequent to mild folate depletion as compared to cells grown with supraphysiological amounts of folate (2 microM) routinely used in tissue culture.
  • These results provide a strong rationale for studying the effects of folate manipulation on the prostate in vivo, where cells might be more sensitive to changes in folate status resulting from folate supplementation or antifolate therapeutic approaches.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6872-80 [15286716.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Mutat Res. 2006 Jan 29;593(1-2):80-7 [16144704.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Genome Res. 2006 Oct;16(10):1222-30 [16954539.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10308-14 [17079450.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10349-56 [17079455.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):178-86 [17080009.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):216S-222S [17182829.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):373-90 [17464296.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):524-42 [17896913.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e119 [17855397.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] BMC Genomics. 2007;8:446 [18053125.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Nutr Biochem. 2008 May;19(5):328-35 [17681772.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 18;101(6):432-5 [19276452.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2888-97 [19417083.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Nutr Cancer. 2000;37(2):245-51 [11142099.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Am J Hum Genet. 1979 Mar;31(2):125-35 [36752.001]
  • [Cites] Clin Chem. 1988 Nov;34(11):2357-9 [3141087.001]
  • [Cites] Cell Prolif. 1993 Jul;26(4):327-36 [8343561.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1433-43 [7503794.001]
  • [Cites] DNA Cell Biol. 1996 Mar;15(3):255-62 [8634154.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):31-8 [9097976.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3909-16 [12032829.001]
  • [Cites] Methods. 2002 Jun;27(2):144-9 [12095273.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):69-75 [12359353.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):453-8 [12355068.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2071-6 [9395204.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):81-90 [12538352.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):375-80 [12653642.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3740S-3747S [14608108.001]
  • [Cites] Mutat Res. 2004 Apr 14;548(1-2):53-9 [15063136.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • (PMID = 20092614.001).
  • [ISSN] 1741-7007
  • [Journal-full-title] BMC biology
  • [ISO-abbreviation] BMC Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21 CA131646; United States / NCI NIH HHS / CA / CA016056; United States / NCI NIH HHS / CA / R21 CA121216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine
  • [Other-IDs] NLM/ PMC2845099
  •  go-up   go-down


47. Aliaev IuG, Vinarov AZ, Lokshin KL, Spivak LG: [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy]. Urologiia; 2007 Mar-Apr;(2):80-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extracts Serenoa repens in the treatment of prostatic adenoma and chronic abacterial prostatitis: results of short-term (3-month courses) therapy].
  • [MeSH-major] Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Serenoa / chemistry

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578203.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts
  • [Number-of-references] 33
  •  go-up   go-down


48. Borisov VB: [Treatment of prostatic adenoma]. Urologiia; 2010 Jul-Aug;(4):42-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of prostatic adenoma].
  • We used lymphotropic therapy in addition to standard treatment in 116 of 232 patients with benign prostatic hyperplasia.
  • Improvement in general condition of the patients, symptoms of infravesical obstruction, size of the prostate, urinary flow rate demonstrated high efficacy of lymphotropic therapy leading to a higher rate of persistent remission and higher quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-1 Receptor Antagonists / therapeutic use. Anti-Bacterial Agents / therapeutic use. Finasteride / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967982.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adjuvants, Immunologic; 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Sulfonamides; 57GNO57U7G / Finasteride; EC 3.2.1.- / lidase; EC 3.2.1.35 / Hyaluronoglucosaminidase; G3P28OML5I / tamsulosin
  •  go-up   go-down


49. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN: [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection]. Urologiia; 2008 Jan-Feb;(1):27, 29, 31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection].
  • Finasteride effect before transurethral resection (TUR) of the prostatic gland was studied in 88 patients with prostatic adenoma (PA).
  • Finasteride reduced blood flow in prostatic tissue, density of the vascular plexus, epithelium/stroma coefficient from 1.26 to 0.84.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Preoperative Care. Prostate / surgery. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652018.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


50. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • These prostatic adenocarcinomas are analogous to nonurachal adenocarcinomas arising in the bladder from cystitis glandularis.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • Mean patient age at diagnosis was 72 years (range 58 to 93 y).
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Immunohistochemical stains were negative for prostate specific antigen, prostate specific acid phosphatase, CDX2, and beta-catenin in all cases.
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Cell Differentiation. Diagnosis, Differential. Follow-Up Studies. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Time Factors. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


51. Ciccarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G, Colao A: PRL secreting adenomas in male patients. Pituitary; 2005;8(1):39-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PRL secreting adenomas in male patients.
  • Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma.
  • [MeSH-minor] Age Factors. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Humans. Libido. Male. Prevalence. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / physiopathology. Semen / physiology. Sex Factors. Spermatogenesis. Testis / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Oct 31;352(9138):1455-61 [9808008.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2102-7 [9215279.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1704-11 [15070934.001]
  • [Cites] Biol Reprod. 1995 Jun;52(6):1284-90 [7632836.001]
  • [Cites] Prostate. 1994;24(3):162-6 [8115281.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):621-5 [14764772.001]
  • [Cites] Eur J Endocrinol. 2003 Mar;148(3):325-31 [12611613.001]
  • [Cites] J Androl. 1991 May-Jun;12(3):185-90 [1917682.001]
  • [Cites] Invest Urol. 1976 Jul;14(1):20-2 [955845.001]
  • [Cites] Eur J Endocrinol. 1998 Mar;138(3):286-93 [9539303.001]
  • [Cites] Endocr Rev. 1998 Jun;19(3):225-68 [9626554.001]
  • [Cites] J Urol. 1989 Oct;142(4):992-4 [2795758.001]
  • [Cites] Mayo Clin Proc. 1998 Nov;73(11):1046-52 [9818037.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2338-43 [8964874.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2770-5 [15181056.001]
  • [Cites] Eur J Endocrinol. 1996 Nov;135(5):548-52 [8980156.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 16411067.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  • [Number-of-references] 20
  •  go-up   go-down


52. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • These are the symptoms that lead to the diagnosis of the primary tumor.
  • It has to be kept in mind that urogenital tumors with such symptoms have to be included in the differential diagnosis.
  • [MeSH-major] Pelvic Neoplasms. Prostatic Hyperplasia. Prostatic Neoplasms. Urethral Neoplasms. Urinary Bladder Neoplasms
  • [MeSH-minor] Cystectomy. Cystoscopy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prostatectomy. Quality of Life. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Vishnevsiĭ EL, Loran OB, Saenko VS: [Sympathic hyperactivity and reservoir function of the bladder in men]. Urologiia; 2010 Sep-Oct;(5):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group 2 patients (n = 23) with prostatic adenoma have undergone uroflowmetric monitoring before and after treatment with doxasozine (640 uroflowgrams).
  • It may be a humoral process mediated by vasoconstriction and disorder of vesical blood flow.
  • [MeSH-minor] Adrenergic alpha-Antagonists / administration & dosage. Aged. Aged, 80 and over. Heart Rate / drug effects. Humans. Male. Middle Aged. Organ Size / drug effects. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / physiopathology

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21254643.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


54. Kolbasov DN: [Hyperbaric oxygenation in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):92-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hyperbaric oxygenation in patients with prostatic adenoma].
  • [MeSH-major] Hyperbaric Oxygenation. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526884.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 41
  •  go-up   go-down


55. Stravodimos KG, Petrolekas A, Kapetanakis T, Vourekas S, Koritsiadis G, Adamakis I, Mitropoulos D, Constantinides C: TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int Urol Nephrol; 2009 Dec;41(4):767-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up?
  • This tactic however might not be optimum since data exist on the superiority of TRUS over transabdominal ultrasound in accurately predicting prostate volumes.
  • We aimed to evaluate TRUS as a standard tool in the evaluation of patients with benign prostate hyperplasia (BPH) with a special focus on the potential impact it might have on the decision of open versus transurethral surgery.
  • PATIENTS AND METHODS: Seventy-one patients presenting with LUTS due to BPH and eventually managed with open surgery based on their preference and prostate volume were included in the protocol.
  • These were compared with respective transabdominal calculations of the prostate volume as well as the enucleated specimen weight (W).
  • CONCLUSION: TRUS is more accurate than transabdominal ultrasound in predicting adenoma volume in patients with BPH and its standard use might lead to fewer open approaches, with consequent less morbidity and hospitalization.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / diagnostic imaging. Ultrasound, High-Intensity Focused, Transrectal / methods. Urinary Tract Infections / diagnosis
  • [MeSH-minor] Abdomen / diagnostic imaging. Adenoma / diagnostic imaging. Aged. Aged, 80 and over. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Organ Size. Predictive Value of Tests. Preoperative Care / methods. Preoperative Care / standards. Probability. Prostatic Neoplasms / diagnostic imaging. Regression Analysis. Risk Assessment. Sensitivity and Specificity. Severity of Illness Index. Treatment Outcome. Ultrasonography, Doppler / methods


56. Miariatskas G, Aliakna V, Cheremnykh E: [Prevalence of enuresis in old males according to questionnaire data]. Urologiia; 2007 Mar-Apr;(2):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk to develop continuous incontinence grows in the presence of Parkinson's disease (OR = 3.50; 95% CI = 1.01-12.23), prostatic adenoma (OR = 5.29; 95% CL = 2.91-9.65).

  • MedlinePlus Health Information. consumer health - Bedwetting.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578196.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


57. Giovannucci E, Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology; 2007 May;132(6):2208-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas.
  • Recent evidence indicates that obesity and related metabolic abnormalities are associated with increased incidence or mortality for a number of cancers, including those of the colon, prostate, and pancreas.
  • Obesity, physical inactivity, visceral adiposity, hyperglycemia, and hyperinsulinemia are relatively consistent risk factors for colon cancer and adenoma.
  • For prostate cancer, the relationship to obesity appears more complex.
  • Obesity seems to contribute to a greater risk of aggressive or fatal prostate cancer but perhaps to a lower risk of nonaggressive prostate cancer.
  • Furthermore, men with type 2 diabetes mellitus are at lower risk of developing prostate cancer.
  • [MeSH-major] Colonic Neoplasms / physiopathology. Diabetes Mellitus, Type 2 / complications. Obesity / complications. Pancreatic Neoplasms / physiopathology. Prostatic Neoplasms / physiopathology


58. Blah M, Gobet F, Dugardin F, Catovic B, Loisel F, Pfister C: [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?]. Prog Urol; 2008 Feb;18(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elevation of total PSA after intravesical BCG instillations: granulomatous prostatitis or prostatic adenocarcinoma?].
  • [Transliterated title] Elévation du PSA total après instillations endovesicales de BCG: prostatite granulomateuse ou adénocarcinome prostatique?
  • OBJECTIVE: The objective of this study was to evaluate the incidence of prostatic carcinoma in patients treated by intravesical BCG-therapy for superficial bladder cancer and presenting granulomatous prostatitis.
  • The authors discuss the problems of interpretation of total PSA and the potential indications for prostatic biopsies in this population.
  • Ultrasound-guided biopsies were indicated in view of the persistently elevated PSA level and confirmed the tuberculoid granulomatous lesion of the prostate in each case and revealed prostatic adenocarcinoma in two patients.
  • CONCLUSION: Prostatic carcinoma must be systematically excluded by ultrasound-guided biopsies in all patients with clinical granulomatous prostatitis and persistently elevated PSA three months after intravesical BCG instillations.
  • [MeSH-major] Adenoma / diagnosis. BCG Vaccine / administration & dosage. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Prostatitis / diagnosis. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Diagnosis, Differential. Drug Administration Schedule. Humans. Male. Retrospective Studies


59. Davidov MI: [Factors predisposing to acute urine retention in patients with prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):25-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors predisposing to acute urine retention in patients with prostatic adenoma].
  • The aim of the trial was to study factors predisposing to acute urine retention (AUR) in patients with prostatic adenoma (PA).
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention / epidemiology. Urinary Retention / etiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580384.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


60. Yuh B, Laungani R, Perlmutter A, Eun D, Peabody JO, Mohler JL, Stricker H, Guru KA: Robot-assisted Millin's retropubic prostatectomy: case series. Can J Urol; 2008 Jun;15(3):4101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION/OBJECTIVE: Simple prostatectomy continues to be an effective surgical option for patients with symptomatic high volume benign prostatic hyperplasia.
  • Recent trends towards minimally invasive urologic surgery, in particular for prostate cancer, have created surgical alternatives with additional potential benefits.
  • Average preoperative transrectal ultrasound estimated prostate volume exceeded 300 cm3.
  • RESULTS: Average age for the patient group was 76.7 years with mean prostate specific antigen (PSA) of 25.1.
  • The patient with the largest prostate required incision extension for removal of specimen.
  • Average adenoma weight was 301 grams (66-640).
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Prostatic Hyperplasia

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570717.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


61. Pushkar' DIu, Dul'kin LM, Pletner DL, Bormotin AV, Liaginskiĭ AB: [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):22-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma].
  • The aim of our study was assessment of efficacy of PLFT technique on ProstaLund CoreTHerm unit in nanagement of acute urine retention in patients with prostatic adenoma.
  • We treated 31 patients with prostatic adenoma (age 58-97, mean age 74 years, volume of the prostatic gland from 32 to 188 ml); 11 patients had suprapubic fistula, 8 carried urethral catheter for acute urinary retention.
  • PLFT destroyed 15 +/- 5% prostatic tissue in each of the treated patients.
  • Thus, PLFT is a highly effective and save treatment of prostatic adenoma and can be recommended as a standard management of patients with acute urinary retention at high surgical risk.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. Recovery of Function. Transurethral Resection of Prostate / methods. Urination

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169717.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


62. Zhao Y, Chen J, Wang M, Sun P, Li L, Zhang H, Jin X: Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients. Saudi Med J; 2010 Dec;31(12):1320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients.
  • OBJECTIVE: To evaluate the safety and effectiveness of the combined photoselective vaporization of the prostate (PVP) and bipolar transurethral resection of the prostate (TURP) in high-risk symptomatic patients with large prostates.
  • One hundred and one patients presenting with various kinds of systematic diseases, and with an American Society of Anesthesiologists score of 3 or greater underwent PVP plus bipolar TURP for severe lower urinary tract symptoms due to benign prostatic hyperplasia with prostatic volume greater than 80 ml.
  • The International Prostate Symptom Score (IPSS) and quality-of-life questionnaire (IPPS-QoL), maximum flow rates (Qmax), postvoid urine residues (PVR), and MRI prostatic volumes were recorded.
  • The mean pre- and post- operative prostate volumes were 102.2 ± 33.1 ml and 40.4 ± 15.6 ml.
  • [MeSH-major] Adenoma / therapy. Prostatic Neoplasms / therapy. Transurethral Resection of Prostate. Volatilization

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21135994.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


63. Gkritsios P, Fotas A, Bekas M, Adamou V, Katsikas V: Thirty years old man with a huge benign prostatic enlargement. Arch Ital Urol Androl; 2010 Jun;82(2):116-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thirty years old man with a huge benign prostatic enlargement.
  • Imaging revealed an enormous prostatic mass.
  • Combining this finding with elevated PSA values, lead us to prostatic biopsies which proved to be benign.
  • Following our advice, the patient had children and afterwards he had his prostate removed.
  • The suprapubic prostatectomy was extremely challenging with a lot of technical difficulties, considering that the net weight of the removed adenoma was 250gr.
  • Pathological examination of the tissue proved that it was benign prostatic hyperplasia.
  • Our case is particularly interesting for two reasons: On one hand because of the unusual size of the prostate and on the other hand because of the young age of the patient.
  • Epidemiological studies showed that prostatic hyperplasia has been pathologically proved only after the age of 40, while pathological signs of the disease could be found after the age of 30.
  • Concerning the size of the adenoma, a search in the literature showed that only 4% of the removed glands weight more than 100 gr, and that has to do with men over 70 years of age.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812537.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


64. Miller AM, Iaroshenko VP, Soroka PV, Stakhnev EIu: [Efficacy of vitaprost forte in patients with prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):50, 52-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in patients with prostatic adenoma].
  • The trial of a new bioregulatory peptide vitaprost forte (100 mg rectal suppositoria) in 30 patients with prostatic adenoma demonstrated that this drug attenuates clinical symptoms of the disease, improves quality of life, uroflowmetric parameters and reduces size of the prostate.
  • Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069497.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


65. Tienari J, Lehtonen S, Lehtonen E: CD2-associated protein in human urogenital system and in adult kidney tumours. Virchows Arch; 2005 Apr;446(4):394-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urothelium and the epithelium of prostatic acini, seminal vesicles, seminiferous tubules, epididymal ducts, Fallopian tube, endometrium and endocervix as well as granulosa cells showed moderate to strong CD2AP positivity.
  • Type-I papillary RCCs (n=4) and papillary adenomas (n=3) were negative.
  • The results show that CD2AP displays a specific expression pattern in human urogenital organs and that distinct expression is shown in several types of kidney tumours but not in type-I papillary RCCs or in papillary adenomas.
  • [MeSH-major] Adenoma / metabolism. Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Proteins / metabolism. Urogenital System / metabolism. src Homology Domains / physiology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 1999 Dec;36(6):565-9 [10559609.001]
  • [Cites] Am J Clin Pathol. 1999 Apr;111(4):539-43 [10191776.001]
  • [Cites] J Am Soc Nephrol. 2002 Sep;13(9):2384-98 [12191984.001]
  • [Cites] Eur Urol. 2000 Apr;37(4):484-7 [10765081.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1467-73 [9811338.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2303-8 [11733379.001]
  • [Cites] Am J Nephrol. 2003 Jul-Aug;23(4):277-86 [12853730.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):237-45 [2565618.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32888-93 [10913159.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):537-44 [9195569.001]
  • [Cites] J Cell Physiol. 1997 Nov;173(2):147-51 [9365514.001]
  • [Cites] APMIS Suppl. 1988;4:48-55 [2465011.001]
  • [Cites] Am J Physiol Renal Physiol. 2000 Oct;279(4):F785-92 [10997929.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1984 Spring;6(1):27-32 [6324606.001]
  • [Cites] Cell. 1998 Sep 4;94(5):667-77 [9741631.001]
  • [Cites] J Am Soc Nephrol. 1995 Jan;5(7):1462-8 [7703384.001]
  • [Cites] Cell. 1995 Apr 21;81(2):289-98 [7736581.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1439-44 [11705510.001]
  • [Cites] Am J Kidney Dis. 1987 Jan;9(1):27-38 [3812480.001]
  • [Cites] J Anat. 1981 Jun;132(Pt 4):597-605 [7028707.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):281-91 [11859199.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6211-6 [10339567.001]
  • [Cites] Am J Surg Pathol. 1997 Jan;21(1):1-12 [8990136.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):203-10 [10680888.001]
  • [Cites] Am J Clin Pathol. 1991 May;95(5):633-7 [2024622.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1721-9 [10362797.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):145-55 [12819019.001]
  • [Cites] Histopathology. 2002 Jun;40(6):563-7 [12047768.001]
  • [Cites] Science. 1996 May 31;272(5266):1339-42 [8650545.001]
  • [Cites] J Urol. 1997 Aug;158(2):370-4 [9224305.001]
  • [Cites] Br J Urol. 1998 Jul;82(1):16-20 [9698657.001]
  • [Cites] Urology. 2002 Sep;60(3):421-7 [12350478.001]
  • [Cites] Science. 2003 May 23;300(5623):1298-300 [12764198.001]
  • [Cites] Science. 1999 Oct 8;286(5438):312-5 [10514378.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(14):4917-28 [12832477.001]
  • (PMID = 15785926.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / CD2-associated protein; 0 / Cytoskeletal Proteins; 0 / Proteins
  •  go-up   go-down


66. Hameed O, Humphrey PA: Immunohistochemistry in diagnostic surgical pathology of the prostate. Semin Diagn Pathol; 2005 Feb;22(1):88-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry in diagnostic surgical pathology of the prostate.
  • Immunohistochemistry (IHC) can play an important role in diagnostic surgical pathology of the prostate.
  • Basal cell markers, such as the 34betaE12 antibody and antibodies directed against cytokeratin 5 and 6 or p63, are very useful for demonstration of basal cells as their presence argues against a diagnosis of invasive prostatic carcinoma (PC).
  • However, several benign mimickers of PC, including atrophy, atypical adenomatous hyperplasia (AAH), nephrogenic adenoma, and mesonephric hyperplasia, can stain negatively with these markers, and thus, a negative basal cell marker immunostain alone does not exclude a diagnosis of benignancy.
  • Although there are examples in the literature of high grade PC that stain focally with some of the basal cell markers, these cases are usually readily diagnosed based on H&E appearances and are unlikely to be confused with these benign mimickers.
  • Alpha-methylacyl-coenzyme-A racemase (AMACR) is a sensitive marker of PC (except for a few uncommon variants: atrophic, foamy gland, and pseudohyperplastic variants), and its detection by immunohistochemical staining in atypical prostatic lesions can be very useful in confirming an impression of adenocarcinoma.
  • AMACR expression can also be identified in high grade prostatic intraepithelial neoplasia (PIN), prostatic atrophy, AAH, and benign prostatic glands, and accordingly, a diagnosis of PC should not be based solely on a positive AMACR immunostain, especially when the luminal staining is weak and/or noncircumferential.
  • The use of AMACR/basal cell antibody cocktails has been found to greatly facilitate the distinction between PC and its benign mimickers, especially when only limited tissue is available for staining.
  • Prostate specific antigen (PSA) and prostate specific acid phosphatase (PSAP) are both quite sensitive and fairly specific markers of PC (there are a few nonprostatic tumors that can express one or both), and are both very helpful in establishing or confirming the diagnosis of PC when the differential diagnosis includes other tumors that can involve the prostate such as urinary bladder urothelial carcinoma.
  • 34betaE12, p63, thrombomodulin, and uroplakin III are additional urothelial associated markers useful in this differential diagnosis.
  • PSA and PSAP immunohistochemical stains are valuable in confirming metastatic carcinoma as being of prostatic origin and should always be utilized in the diagnostic evaluation of metastatic adenocarcinoma of unknown primary origin in males.
  • [MeSH-major] Carcinoma / diagnosis. Immunohistochemistry. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Humans. Leukemia / diagnosis. Lymphoma / diagnosis. Male. Neoplasm Metastasis. Sarcoma / diagnosis. Sensitivity and Specificity. Urinary Bladder Neoplasms / diagnosis


67. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H: Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique. Urol Int; 2005;74(2):102-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique.
  • OBJECTIVE: Transurethral resection of the prostate (TURP) leaves a lot of residual adenoma and has a high recurrence rate, but the residual adenoma weight has not been measured surgically.
  • Using surgery we tried to measure the residual adenoma after TURP.
  • MATERIAL AND METHODS: Total adenoma resection was performed via standard TURP in 64 cases with benign prostatic hyperplasia and the weight of the residual adenoma was measured by transurethral enucleation (TUE) of the prostate.
  • RESULTS: Prostate volume averaged 37.4 ml and adenoma volume averaged 20.6 ml by TRUS.
  • The average weight of the prostate removed by TURP was 9.8 g.
  • After TURP residual adenoma was confirmed in all cases by TUE, and the average weight of the residual adenoma was 10.2 g.
  • The total average prostate volume removed by TURP and TUE was 20.1 g.
  • The average residual rate of the adenoma removed by TURP was 54.5%.
  • CONCLUSION: TURP leaves about half of the adenoma.
  • Therefore, TURP might be very difficult for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756059.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


68. Abdel-Khalek M, Sheir KZ, El-Baz M, Ibrahiem el-H: Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy? Scand J Urol Nephrol; 2005;39(1):49-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
  • OBJECTIVES: To evaluate the importance of transition zone (TZ) biopsy in benign prostatic hyperplasia (BPH) patients with serum prostate-specific antigen (PSA) >10 ng/ml and prior negative peripheral zone (PZ) biopsy and to estimate the sensitivity of TZ biopsy.
  • Overall, 215 patients were subjected to either transurethral resection of the prostate (n=162) or open enucleation of the adenoma (n=53).
  • RESULTS: The extended biopsy revealed prostate cancers in 21.2% of cases (58/273).
  • Prostate volume (p=0.023), TZ volume (p=0.027) and PSA/TZ density (p=0.007) were predictive of TZ cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Prostate / pathology. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / pathology
  • [MeSH-minor] Aged. Biopsy. Humans. Incidence. Male. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / epidemiology. Sensitivity and Specificity


69. Kamalov AA, Efremov EA, Dorofeev SD, Mel'nik IaI, Okhobotov DA: [Vitaprost forte in the therapy of patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):39-44, 47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte in the therapy of patients with prostatic adenoma].
  • Active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland.
  • Prostatic extract has an organotropic effect in respect to the prostatic gland.
  • It inhibits proliferative activity of cells and, therefore, development of prostatic adenoma, reduces edema and inflammation activity in prostatic diseases.
  • Our study has shown that rectal suppositories vitaprost forte, as monotherapy of prostatic adenoma, produces a statistically significant moderate decrease of prostate size.
  • Rectal suppositories vitaprost forte can be used as monotherapy of prostatic adenoma in patients with moderate infravesical obstruction irrespective of age and concurrent diseases.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Animals. Cattle. Drug Administration Schedule. Humans. Male. Organ Size. Prostate / chemistry. Prostate / pathology. Sulfonamides / administration & dosage. Sulfonamides / therapeutic use. Suppositories. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722619.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Sulfonamides; 0 / Suppositories; 0 / Vitaprost; G3P28OML5I / tamsulosin
  •  go-up   go-down


70. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


71. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA: Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int; 2006 Jun;97(6):1229-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
  • The authors used preoperative PSA level as a marker of prostate volume and assessed its potential predictive value on the level of clinical efficacy for treating symptomatic BPH.
  • OBJECTIVE: To report the 3-year results and analyse whether total prostate-specific antigen (tPSA) levels and prostate volume before treatment can predict the level of clinical efficacy of photoselective vaporization prostatectomy (PVP) for treating obstructive benign prostatic disease, as high-power potassium-titanyl-phosphate (KTP) laser prostatectomy was previously shown to be safe and to efficiently vaporize prostatic adenoma secondary to benign prostatic hyperplasia (BPH), with minimal bleeding and morbidity.
  • A subanalysis evaluating each patient for tPSA and prostate volume before PVP was conducted, with a long-term assessment of the primary efficacy outcomes at 3 years after PVP.
  • Each subgroup was assessed for changes from baseline in American Urological Symptom Index (AUA SI) score, quality of life (QoL) score, peak urinary flow rate (Q(max)), prostate volume, and postvoid residual urine volume (PVR) at 1, 2 and 3 years after PVP.
  • The mean (sd) prostate volume for group 1 was 48.3 (16.7) mL (87 men), and was 83.1 (30.6) mL (52 men) in group 2.
  • However, the overall results achieved with PVP were very positive and durable to 3 years, irrespective of tPSA level and prostate volume.
  • [MeSH-major] Laser Therapy / methods. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Urologic Diseases / surgery


72. Müller RM, Thalmann GN, Studer UE: [Old and new interventional therapies in the treatment of symptomatic benign prostate hyperplasia (BPH)]. Ther Umsch; 2006 Feb;63(2):129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Old and new interventional therapies in the treatment of symptomatic benign prostate hyperplasia (BPH)].
  • Benign Prostatic Hyperplasia is a common entity among the aging male population.
  • The androgen-estrogen ratio changes in favor of the estrogens, which leads to a growth of prostatic tissue, presenting histologically as hyperplasia.
  • LUTS has a structural and a functional component, the structural being caused by the size of the adenoma itself the functional depending on the muscle tone of the bladder neck and the prostatic urethra.
  • Electro-resection of the prostate (TUR-P) remains the standard therapy and the benchmark any new technology has to compete with.
  • The most promising of the newer techniques is the Holmium-Laser-Enucleation of the prostate (Laser-TUR-P), showing at least identical short- and median-term results, but a lower perioperative morbidity than TUR-P For several minimally-invasive techniques, indications are limited.
  • TUMT TUNA, WIT and laser-coagulation all produce a coagulation necrosis of the prostatic tissue by thermic damage with secondary tissue shrinking.
  • [MeSH-major] Catheter Ablation / methods. Laser Therapy / methods. Minimally Invasive Surgical Procedures / methods. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514965.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 18
  •  go-up   go-down


73. Hiraoka Y, Shimizu Y, Iwamoto K, Takahashi H, Abe H: Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate. Urol Int; 2007;79(1):50-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate.
  • INTRODUCTION: We tried a complete detachment of the whole prostate lobes for benign prostate hyperplasia (BPH) by transurethral enucleation of the prostate (TUE).
  • MATERIALS AND METHODS: For 46 BPH cases the whole prostate lobes were detached from the surgical capsule completely by a prostate-detaching blade and resectoscope beak, and dropped into the bladder.
  • The detached prostate lobes were removed by a soft tissue morcellator.
  • The preoperative total prostate and adenoma volume by transabdominal ultrasound measurement (TAUS) were 47.75 +/- 25.63 and 27.8 +/- 17.33 ml.
  • RESULTS: In all 46 BPH cases, the whole prostate lobes could be detached completely without a perforation.
  • Postoperative prostate volume and PSA were decreased to 9.56 ml and 0.8 ng/ml with complete removal of an adenoma.
  • CONCLUSIONS: TUDP could achieve complete removal of even a large adenoma without perforation, transurethral resection syndromes and blood transfusion safety.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery


74. Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ: The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU Int; 2005 Nov;96(7):1045-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
  • OBJECTIVES: To compare the clinical profile (age, comorbidities, symptom severity, and incidence of acute urinary retention, AUR), the type and duration of medical treatment, and indications for surgery of patients undergoing surgery for benign prostatic hyperplasia (BPH) in 1992 and 2002 at one centre.
  • The preoperative clinical profile was determined by assessing age, main comorbidities, prostatic volume, maximum urinary flow rate and symptom severity.
  • Open surgery was indicated in 18.8% of patients in 1992 (mean adenoma weight 73.8 g, sd 37.12) and in 28.6% in 2002 (79.8 g, sd 35.41; P = 0.625).
  • Significantly more patients had open surgery, perhaps because the progressive increase in prostate volume was not affected by the medical therapy used predominantly during this decade.
  • [MeSH-major] Adenoma / surgery. Patient Selection. Prostatectomy / trends. Prostatic Hyperplasia / surgery
  • [MeSH-minor] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / therapeutic use. Age Factors. Aged. Chi-Square Distribution. Cross-Sectional Studies. Disease Progression. Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Humans. Male. Middle Aged. Phytotherapy / utilization. Prostate / surgery. Retrospective Studies

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225526.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


75. Elhilali M: Editorial comment. Urology; 2010 Dec;76(6):1455-6; author reply 1456
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Urinary Incontinence, Stress / prevention & control
  • [MeSH-minor] Aged. Dissection / methods. Hemostasis, Surgical. Humans. Male. Middle Aged. Organ Size. Prostate / pathology


76. [Prostatic adenoma and overactive urinary bladder: assessment of symptoms and choice of therapy]. Urologiia; 2009 Mar-Apr;(2):78, 80-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic adenoma and overactive urinary bladder: assessment of symptoms and choice of therapy].
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Urinary Bladder, Overactive / physiopathology. Urinary Bladder, Overactive / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526881.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


77. Porpiglia F, Terrone C, Renard J, Grande S, Musso F, Cossu M, Vacca F, Scarpa RM: Transcapsular adenomectomy(Millin): a comparative study, extraperitoneal laparoscopy versus open surgery. Eur Urol; 2006 Jan;49(1):120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From January 2003 to April 2005, patients, with indication of prostatic adenomectomy, were offered the chance to choose between 2 types of procedure: Millin adenomectomy with open or extraperitoneal laparoscopic approach.
  • Mean adenoma weight in Group A was: 69,5+/-21.5 g, in Group B: 88.1+/-43.8 g.
  • [MeSH-major] Laparoscopy. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2006 Jun;49(6):1136; author reply 1136-7 [16632193.001]
  • [CommentIn] Eur Urol. 2007 May;51(5):1450-1 [17239526.001]
  • (PMID = 16310927.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


78. Byun SS, Jeong H, Jo MK, Lee E: Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men? Urology; 2005 Sep;66(3):593-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
  • OBJECTIVES: To investigate the high prevalence of lower urinary tract symptoms in Korean men with a small prostate, we studied the proportions of histologic components of prostatic adenoma in patients with symptomatic benign prostatic hyperplasia.
  • METHODS: Prostatic adenoma specimens were obtained from men with symptomatic benign prostatic hyperplasia who underwent open prostatectomy or transurethral resection of the prostate.
  • Patients were divided into three groups according to the prostate volume as measured by preoperative transrectal ultrasonography (group 1, 20 to 40 cm3, 21 men; group 2, 41 to 80 cm3, 22 men; and group 3, greater than 80 cm3, 23 men).
  • The proportion of the stroma in the prostatic adenoma and the proportions of smooth muscle, collagen types I, II, III, and V, fibronectin, and laminin in stromal tissue were determined using automatic image analyzer quantitatively.
  • RESULTS: The proportions of the stroma in the prostatic adenoma specimens of groups 1 and 2 were significantly greater than in group 3 (P < 0.05).
  • The relative smooth muscle proportion in the prostatic adenoma (proportion of stroma x proportion of smooth muscle in stromal tissue) in groups 1 and 2 was significantly greater than in group 3 (P < 0.05).
  • CONCLUSIONS: These results suggest that the dynamic component of bladder outlet obstruction, which is mediated by smooth muscle tone, may play a more important role in the development of symptomatic benign prostatic hyperplasia in Korean men.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140084.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Verschoyle RD, Greaves P, Patel K, Marsden DA, Brown K, Steward WP, Gescher AJ: Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. Eur J Cancer; 2008 Apr;44(6):898-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels.
  • We tested the hypotheses that silibinin or silipide, silibinin formulated with phospholipids, delays tumour development in TRAMP or Apc(Min) mice, genetic models of prostate or intestinal malignancies, respectively.
  • In Apc(Min) mice silibinin, but not silipide, had only a marginal adenoma number-reducing effect.
  • The results cautiously support the advancement of silipide to the stage of clinical investigation in prostate cancer.
  • [MeSH-major] Adenoma / prevention & control. Anticarcinogenic Agents / therapeutic use. Intestinal Neoplasms / prevention & control. Phosphatidylcholines / therapeutic use. Prostatic Neoplasms / prevention & control. Silymarin / therapeutic use

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343654.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C325/A6691; United Kingdom / Medical Research Council / / G0100874
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / Phosphatidylcholines; 0 / Silymarin; 134499-06-2 / IdB 1016; 4RKY41TBTF / silybin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


80. Hameed O, Humphrey PA: Pseudoneoplastic mimics of prostate and bladder carcinomas. Arch Pathol Lab Med; 2010 Mar;134(3):427-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoneoplastic mimics of prostate and bladder carcinomas.
  • CONTEXT: The differential diagnoses of prostatic carcinoma and bladder epithelial neoplasms include several histologic mimics that should be known to avoid misdiagnosis.
  • OBJECTIVE: To discuss pseudoneoplastic lesions of the prostate and bladder that could potentially be confused with prostatic carcinoma and bladder epithelial neoplasms, respectively, with specific focus on their distinguishing histopathologic features.
  • CONCLUSIONS: Pseudoneoplastic lesions in the prostate include those of prostatic epithelial origin, the most common being atrophy, adenosis (atypical adenomatous hyperplasia), basal cell hyperplasia, and crowded benign glands, as well as those of nonprostatic origin, such as seminal vesicle epithelium.
  • Such lesions often mimic lower-grade prostatic adenocarcinoma, whereas others, such as clear cell cribriform hyperplasia and granulomatous prostatitis, for example, are in the differential diagnosis of Gleason adenocarcinoma, Gleason grade 4 or 5.
  • Several lesions can mimic invasive urothelial carcinoma, including pseudocarcinomatous hyperplasia, von Brunn nests, and nephrogenic adenoma.
  • Diagnostic awareness of the salient histomorphologic and relevant immunohistochemical features of these prostatic and urinary bladder pseudoneoplasms is critical to avoid rendering false-positive diagnoses of malignancy.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Prostatic Diseases / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Prostatic Neoplasms / classification. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / classification. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196670.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 83
  •  go-up   go-down


81. Ergakov DV, Martov AG, Maksimov VA: [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit]. Urologiia; 2009 Jan-Feb;(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
  • We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate.
  • Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions).
  • [MeSH-major] Phytotherapy. Plant Preparations / administration & dosage. Postoperative Care. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432230.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


82. Varshney A, Agarwal A: Against the motion: Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world. Indian J Urol; 2009 Jul;25(3):409-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Against the motion: Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world.
  • Lasers have arrived in a big way for the management of benign prostatic hyperplasia.
  • The most common ones in use are holmium, potassium titanyl phosphate (KTP) and thulium.They remove the prostatic adenoma either by way of enucleation or ablation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1465-9 [12352419.001]
  • [Cites] J Urol. 2000 Jun;163(6):1730-3 [10799170.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):744-9 [17475395.001]
  • [Cites] Eur Urol. 2008 Feb;53(2):382-89 [17566639.001]
  • [Cites] BJU Int. 2007 Sep;100(3):593-8; discussion 598 [17511771.001]
  • [Cites] Curr Opin Urol. 2007 Jan;17(1):27-31 [17143108.001]
  • [Cites] Eur Urol. 2006 Sep;50(3):563-8 [16713070.001]
  • [Cites] BJU Int. 2006 Jan;97(1):85-9 [16336334.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1229-33 [16686717.001]
  • [Cites] J Urol. 2006 Apr;175(4):1428-32 [16516015.001]
  • [Cites] Urology. 2006 Jan;67(1):80-3 [16413337.001]
  • [Cites] J Urol. 2006 Feb;175(2):537-40 [16406990.001]
  • [Cites] J Endourol. 2005 Dec;19(10):1196-8 [16359214.001]
  • [Cites] BJU Int. 2006 Jan;97(1):81-4 [16336333.001]
  • [Cites] J Endourol. 2005 Jun;19(5):550-4 [15989443.001]
  • [Cites] J Urol. 2005 Jul;174(1):210-4 [15947629.001]
  • [Cites] Br J Urol. 1997 Feb;79(2):177-80 [9052466.001]
  • [Cites] J Urol. 1989 Feb;141(2):243-7 [2643719.001]
  • [Cites] J Urol. 2004 Aug;172(2):611-5 [15247744.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1270-4 [14501739.001]
  • (PMID = 19881144.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2779973
  •  go-up   go-down


83. Al'-Shukri SKh, Amdiĭ RE: [Value of combined urodynamic examination of patients with unsatisfactory outcomes of surgical treatment of prostatic adenoma]. Urologiia; 2006 Jul-Aug;(4):11-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of combined urodynamic examination of patients with unsatisfactory outcomes of surgical treatment of prostatic adenoma].
  • Forty three patients with unsatisfactory outcomes of surgical treatment of benign prostatic hyperplasia (BPH) were examined urodynamically.
  • Accurate diagnosis of characteristics and causes of lower urinary tracts dysfunction decides choice of adequate therapeutic policy.
  • [MeSH-major] Prostatectomy / adverse effects. Prostatic Hyperplasia / surgery. Urination Disorders / diagnosis. Urodynamics / physiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058672.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


84. Maksimov IB, Sergienko NF, Shchekochikhin AV, Deviatov AS, Baglaĭ GV: [The 20th anniversary of Urological Center of Main Military Clinical Hospital named after N. N. Burdenko]. Voen Med Zh; 2009 Sep;330(9):38-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent diseases--adenoma of prostate, malignant swelling and benign tumour of urological organs, urolithiasis, traumatic damages of urological organs.
  • [MeSH-minor] History, 20th Century. History, 21st Century. Humans. Male. Moscow. Prostatectomy / history. Prostatectomy / methods. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / history. Prostatic Hyperplasia / surgery. Urologic Diseases / diagnosis. Urologic Diseases / history. Urologic Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20020614.001).
  • [ISSN] 0026-9050
  • [Journal-full-title] Voenno-medit︠s︡inskiĭ zhurnal
  • [ISO-abbreviation] Voen Med Zh
  • [Language] rus
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


85. Georgitsi M, Karhu A, Winqvist R, Visakorpi T, Waltering K, Vahteristo P, Launonen V, Aaltonen LA: Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer; 2007 Jan 29;96(2):352-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers.
  • Germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene were recently identified in individuals with pituitary adenoma predisposition (PAP).
  • These patients have prolactin (PRL) or growth hormone (GH) oversecreting pituitary adenomas, the latter exhibiting acromegaly or gigantism.
  • To examine the possible role of AIP in the genesis of common cancers, we performed somatic mutation screening in a series of 373 colorectal cancers (CRCs), 82 breast cancers, and 44 prostate tumour samples.
  • These results suggest that somatic AIP mutations are not common in CRC, breast, and prostate cancers.
  • [MeSH-major] Breast Neoplasms / genetics. Colorectal Neoplasms / genetics. Mutation. Prostatic Neoplasms / genetics. Proteins / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3659-62 [12097271.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4467-73 [12482853.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):99-106 [12622420.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33351-63 [12810716.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):437-50 [14713256.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • [Cites] Eur J Cancer. 1993;29A(4):492-7 [8435198.001]
  • [Cites] Science. 1994 Oct 7;266(5182):120-2 [7939630.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2660-4 [7780982.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3395-402 [8530571.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11452-6 [9111057.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):677-81 [10079245.001]
  • [Cites] Biochemistry. 1999 Jul 13;38(28):8907-17 [10413464.001]
  • [Cites] Oncogene. 1999 Aug 12;18(32):4643-6 [10467410.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33346-56 [16085934.001]
  • [Cites] J Cell Biochem. 2005 Dec 15;96(6):1174-84 [16211578.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Feb;64(2):115-21 [16430706.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Prostate. 2006 Nov 1;66(15):1585-91 [16927275.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32 [10564676.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2193-200 [10829038.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1329-33 [12375043.001]
  • (PMID = 17242703.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  • [Other-IDs] NLM/ PMC2360003
  •  go-up   go-down


86. Arbuliev MG, Zaĭnulabidov ZSh, Mukhamad II, Arbuliev KM: [A variant of transvesical extraurethral adenomectomy]. Urologiia; 2007 Jul-Aug;(4):37-9, 41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To facilitate extraurethral adenomectomy, we used a semicylindric scalpel and metallic tube (tubus) to make a semioval cut parallel to proximal prostatic portion of the urethra along the posterior semicircle of the bladder neck in 260 patients with prostatic adenoma (PA).
  • Extra-urethral adenomectomy with semicylindric scalpel injured prostatic urethra in lesser extent than endourethral adenomectomy, it reduced the risk of hemorrhage, entailed neither stricture of the posterior urethra nor incontinence of urine in the postoperative period.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Urologic Surgical Procedures, Male / instrumentation. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915447.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


87. Kamalov AA, Osmolovskiĭ BE: [Transurethral photoselective laser vaporization in the treatment of prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral photoselective laser vaporization in the treatment of prostatic adenoma].
  • Progress in laser technologies allowed development of a highly effective method of laser adenomectomy--photoselective vaporization of the prostate (PSVP).
  • [MeSH-major] Laser Therapy / instrumentation. Laser Therapy / methods. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069492.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


88. Desai MM, Aron M, Canes D, Fareed K, Carmona O, Haber GP, Crouzet S, Astigueta JC, Lopez R, de Andrade R, Stein RJ, Ulchaker J, Sotelo R, Gill IS: Single-port transvesical simple prostatectomy: initial clinical report. Urology; 2008 Nov;72(5):960-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: To present the initial report of single-port transvesical enucleation of the prostate in 3 patients with large-volume benign prostatic hyperplasia.
  • METHODS: Single-port transvesical enucleation of the prostate was performed in 3 patients with large-volume (187, 93, and 92 g) benign prostatic hyperplasia.
  • After establishing pneumovesicum, the adenoma was enucleated in its entirety transvesically under laparoscopic visualization using standard and articulating laparoscopic instrumentation.
  • The adenoma was extracted through the solitary skin and bladder incision after bivalving the prostate lobes within the bladder.
  • RESULTS: Single-port transvesical enucleation of the prostate was technically feasible in all 3 cases.
  • Additional experience at our and other institutions is necessary to determine its role in the surgical management of large-volume symptomatic benign prostatic hyperplasia.
  • [MeSH-major] Adenoma / surgery. Prostatectomy / methods. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Urology. 2009 Jun;73(6):1425-6; author reply 1426 [19482165.001]
  • (PMID = 18835633.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Zhang Y, Du CJ, Xu G, Chen JM, Jing X: [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g]. Zhonghua Nan Ke Xue; 2007 Dec;13(12):1091-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g].
  • OBJECTIVE: To evaluate the effect of transurethral holmium laser enucleation of the prostate (HoLEP) for prostate adenoma greater than 100 g.
  • METHODS: Sixty BPH patients with the prostate larger than 100 g were randomized to two treatment groups of HoLEP (n = 32) and open prostatectomy (n = 28).
  • Comparisons were made between the two groups in operating time, blood loss, bladder irrigating time, catheterization time and hospital stay, as well as in the international prostate symptom score (IPSS), quality of life (QOL) score, maximum urinary flow rate (Qmax) and postvoid residual volume (PVR) before and 3 months after the surgery.
  • CONCLUSION: HoLEP and open prostatectomy are equally effective procedures for removal of large prostate adenomas, but the former is a better surgical option for prostate adenomas larger than 100 g for its greater safety, less pain and faster recovery.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284057.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  •  go-up   go-down


90. de Roux-Serratrice C, Serratrice J, Champsaur P, Faucher B, Ené N, Granel B, Swiader L, Coulange C, Disdier P, Weiller PJ: [You said, after the fact!...]. Rev Med Interne; 2005 Jul;26 Suppl 2:S282-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [You said, after the fact!...].
  • [Transliterated title] Vous avez dit post-hoc ?...

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129175.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Yun HK, Kwon JB, Cho SR, Kim JS: Early Experience with Laparoscopic Retropubic Simple Prostatectomy in Patients with Voluminous Benign Prostatic Hyperplasia (BPH). Korean J Urol; 2010 May;51(5):323-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early Experience with Laparoscopic Retropubic Simple Prostatectomy in Patients with Voluminous Benign Prostatic Hyperplasia (BPH).
  • PURPOSE: Laparoscopic simple prostatectomy was recently developed to treat voluminous benign prostatic hyperplasia (BPH).
  • The subjects were limited to the patients who satisfied the following conditions: prostate volume was at least 75 g, acute urinary retention repeatedly occurred or maximal flow rate (Qmax) was at most 10 ml/s, and International Prostate Symptom Score (IPSS) was at least 12.
  • Mean preoperative prostate-specific antigen and prostate volume were 6.1 ng/ml and 109.3 cc, respectively.
  • The resected adenoma weighed on average 72.4 g.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Urol. 2010 Feb;51(2):115-21 [20414424.001]
  • [Cites] World J Urol. 2009 Jun;27(3):385-7 [19082604.001]
  • [Cites] Eur Urol. 1999;36 Suppl 3:28-32 [10559628.001]
  • [Cites] J Urol. 2001 Feb;165(2):459-62 [11176396.001]
  • [Cites] Urology. 2001 Nov;58(5):642-50 [11711329.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 2):999-1003; discussion 1004 [11908420.001]
  • [Cites] J Urol. 2002 Jun;167(6):2528-9 [11992078.001]
  • [Cites] Urology. 2002 Oct;60(4):623-7 [12385922.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):530-47 [12853821.001]
  • [Cites] Eur Urol. 2004 Jan;45(1):103-9; discussion 109 [14667525.001]
  • [Cites] Urology. 2004 Apr;63(4):778-9 [15072905.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):547-54 [15474261.001]
  • [Cites] BJU Int. 2005 Mar;95(4):676-8 [15705103.001]
  • [Cites] J Urol. 2005 Mar;173(3):757-60 [15711263.001]
  • [Cites] Eur Urol. 2006 Jan;49(1):127-31; discussion 131-2 [16314034.001]
  • [Cites] J Urol. 2006 May;175(5):1691-4 [16600732.001]
  • [Cites] Eur Urol. 2008 Jan;53(1):160-6 [17869409.001]
  • [Cites] Eur Urol. 2008 Aug;54(2):427-37 [18069117.001]
  • [Cites] Eur Urol. 1999;36 Suppl 3:14-20 [10559626.001]
  • (PMID = 20495695.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2873886
  • [Keywords] NOTNLM ; Laparoscopy / Prostate / Prostatectomy / Prostatic hyperplasia
  •  go-up   go-down


92. Meyskens FL Jr, McLaren CE: Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? J Natl Cancer Inst; 2010 Dec 15;102(24):1815-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma / prevention & control. Breast Neoplasms / prevention & control. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / prevention & control. Celecoxib. Colorectal Neoplasms / prevention & control. Cyclooxygenase 2 Inhibitors / administration & dosage. Cyclooxygenase 2 Inhibitors / adverse effects. Disease Progression. Female. Humans. Keratosis, Actinic / drug therapy. Keratosis, Actinic / pathology. Male. Prostatic Neoplasms / prevention & control. Pyrazoles / administration & dosage. Pyrazoles / adverse effects. Randomized Controlled Trials as Topic. Skin Neoplasms / prevention & control. Sulfonamides / administration & dosage. Sulfonamides / adverse effects. Terminology as Topic

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44 [21115882.001]
  • (PMID = 21115881.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA062203
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


93. Lane Z, Hansel DE, Epstein JI: Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol; 2008 Sep;32(9):1322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
  • Adenocarcinomas of the bladder are rare, with the diagnosis dependent on exclusion of secondary involvement by direct extension or metastatic spread from other sites.
  • The recent description of an unusual form of urothelial-type mucinous prostatic adenocarcinoma raises a novel differential diagnosis between adenocarcinomas of the prostate and bladder, and investigation into the utility of classic prostatic immunohistochemical antigens in bladder adenocarcinoma is warranted.
  • Also included for comparison were 3 cases, each of bladder villous adenomas and bladder adenocarcinoma in situ.
  • Immunohistochemistry for prostate-specific antigen (PSA), prostate specific acid phosphatase (PSAP), P501S (prostein), and prostate specific membrane antigen (PSMA) was performed, and moderate to strong immunoreactivity was considered a positive result.
  • In contrast, a minority of bladder adenocarcinomas was labeled with the prostate antigens P501S and PSMA.
  • The granular perinuclear staining pattern of P501S typically seen in prostatic adenocarcinoma was absent in all cases of bladder adenocarcinoma.
  • Membranous PSMA staining was evident in an additional 3 tumors, 1 urachal mucinous adenocarcinoma, 1 nonurachal mucinous and signet ring cell adenocarcinoma, and 1 nonurachal villous adenoma.
  • In conclusion, although all cases of bladder adenocarcinoma examined were negative for PSA and PSAP, the surprising finding that a subset of invasive and in situ adenocarcinomas of the bladder demonstrated immunoreactivity for P501S and PSMA should warrant caution when using these markers in differentiating prostatic from bladder adenocarcinomas.
  • The lack of granular perinuclear staining for P501S and the absence of membranous PSMA staining both favor a bladder adenocarcinoma, although rare cases of villous adenoma and adenocarcinoma did show PSMA membranous staining indistinguishable from that seen in prostate cancer.
  • Although the novel antigens P501S and PSMA are fairly specific and more sensitive in the differential diagnosis of prostate and urothelial carcinoma, care must be taken when adenocarcinomas of the bladder are considered within this differential diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Villous / metabolism. Antigens, Neoplasm / biosynthesis. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Acid Phosphatase. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Membrane Proteins / biosynthesis. Prostate-Specific Antigen / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Protein Tyrosine Phosphatases / biosynthesis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670358.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Membrane Proteins; 0 / prostein; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


94. Shkol'nikov ME, Iakushkin VR: [Diagnosis and treatment of nocturia in patients with prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of nocturia in patients with prostatic adenoma].
  • [MeSH-major] Nocturia / diagnosis. Nocturia / therapy. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248603.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 63
  •  go-up   go-down


95. Lee SW, Cho JM, Kang JY, Yoo TK: Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion. Korean J Urol; 2010 Oct;51(10):694-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and urodynamic significance of morphological differences in intravesical prostatic protrusion.
  • PURPOSE: The objectives of this study were to evaluate whether morphologic differences correlated with urodynamic and clinical characteristics in patients with benign prostatic hyperplasia (BPH) with intravesical prostatic protrusion (IPP) of trilobar or bilobar adenoma.
  • They underwent preoperative urodynamic studies, the International Prostate Symptom Score (IPSS)/quality of life (QoL), maximal flow rate (Qmax), post-voiding residual urine volume (PVR), transrectal ultrasonography (TRUS), and serum prostate-specific antigen (PSA) measurement.
  • The patients were classified into 2 groups (the trilobar and bilobar adenoma groups) on the basis of video findings during the TUR operation.
  • RESULTS: The trilobar and bilobar adenoma groups consisted of 37 patients and 35 patients, respectively.
  • The Mean±SD IPP, prostate volume (PV), and transition zone volume of the trilobar and bilobar adenoma groups were 11.8±5.2 mm and 9.0±3.8 mm (p=0.014), 81.1±25.8 g and 59.3±22.5 g (p<0.001), and 49.6±20.6 g and 34.8±19.4 g (p=0.003), respectively.
  • The PV, BOOI, and BCI were significantly smaller in the bilobar adenoma group than in the trilobar adenoma group.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21031089.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2963782
  • [Keywords] NOTNLM ; Prostatic hyperplasia / Ultrasonography / Urodynamics
  •  go-up   go-down


96. Trapeznikova MF, Morozov AP, Pozdniakov KV: [Acute urine retention in prostatic adenoma]. Urologiia; 2007 May-Jun;(3):98-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute urine retention in prostatic adenoma].
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722628.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Number-of-references] 77
  •  go-up   go-down


97. Trapeznikova MF, Urenkov SB, Zubrilina NM, Podoĭnitsyn AA: [Current trends in the treatment of urological patients with transplanted kidney]. Urologiia; 2009 Mar-Apr;(2):9-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of the patients had urolithiasis, prostatic adenoma, some patients had renal cyst, implanted kidney tumor, tumor of the arteriosclerotic kidneys, posterior urethra stricture, posterior urethra valve.
  • Kidney recipients with prostatic adenoma (2 and 5 years after transplantation) in 3 cases were subjected to scheduled TUR because of manifest obstructive symptoms.
  • Urethral nitinol stenting was made in one patient with AUR and prostatic size over 60 cm3, TUR was made 4 months later.
  • Prostatic adenoma is treated, as a rule, surgically (TUR of the prostate).
  • [MeSH-major] Kidney Transplantation. Prostatic Hyperplasia / therapy. Urologic Diseases / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526868.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


98. Neĭmark AI, Snegirev IV, Neĭmark BA: [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma]. Urologiia; 2006 Mar-Apr;(2):75, 77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma].
  • The authors analyse preoperative preparation of 91 patients with benign prostatic hyperplasia (BPH).
  • Two groups of patients received conventional preparation (group 1) and magnetotherapy (group 2) before TUR of the prostate.
  • The examination covered immune system, bacteriological indices of urine and prostatic tissue.
  • Conventional preoperative preparation fails to correct immunity, to change bacterial urine flora, to improve hemodynamics in the prostate.
  • [MeSH-major] Ferrosoferric Oxide / therapeutic use. Physical Therapy Modalities / instrumentation. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Tract Infections / prevention & control
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Leukocyte Count. Male. Perioperative Care / methods. Prostate / microbiology. Rectum. T-Lymphocytes / immunology. Urine / microbiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708596.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


99. Oreste M, Giuseppe PG, Gianna P, Adriano A, Stefano N, Mauro B, Carlo V: Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia. World J Urol; 2010 Jun;28(3):379-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia.
  • PURPOSE: We verified if the measure of transition zone epithelial volume (TZepiV) could be a valid predictor of serum PSA value in men with benign prostatic hyperplasia (BPH).
  • In case of an elevated PSA level (above 4 ng/ml) or abnormal digital rectal examination, systematic multisite biopsies were performed preoperatively to rule out prostate cancer.
  • We have examined PSA levels before and after open surgery, TZ weight as measured by the pathologist and TZepiV by multiplying percentage of epithelium of a single biopsy core with the weight of adenoma.
  • The mean decrease in PSA was 90% (range 70-99%).The mean weight of enucleated adenoma was 67 gr.(range 18-201) and the TZepiV was 7.7 ml (0.3-28.4).
  • Thus, TZ epithelial volume could represent a new useful clinical tool able to increase the specificity of PSA in the diagnosis of prostate cancer.
  • [MeSH-major] Adenoma / blood. Adenoma / pathology. Epithelium / pathology. Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Analysis of Variance. Biopsy, Needle. Cohort Studies. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Probability. Prostatectomy / methods. Retrospective Studies. Risk Assessment. Transurethral Resection of Prostate / methods. Treatment Outcome. Tumor Burden


100. Danilov VV, Vasil'chenko AV, Danilova TI, Besedin SA, Borshchenko SA, Danilov VV: [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma]. Urologiia; 2010 Nov-Dec;(6):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma].
  • After examination 47 patients with prostatic adenoma (mean age 63 years) received a course of alpha1-adenoblocker (omsulosin in a dose 0.4 mg/day).
  • Thus, long-term treatment with alpha1-adrenoblockers can be used as a pharmacourodynamic test to detect infravesical obstruction in patients with prostatic adenoma.
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Bladder Neck Obstruction / diagnosis. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427987.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down






Advertisement